Biopeptide Co.

Executive Summary

Biopeptide Co., Inc. is a specialized peptide synthesis service provider founded in 1999 and headquartered in San Diego, USA. The company leverages Fmoc and t-Boc solid-phase and solution-phase technologies to design, synthesize, and produce custom peptides, including difficult sequences, from milligram to multigram scales. Serving leading scientists, pharmaceutical companies, and government agencies, Biopeptide emphasizes quality, fast turnaround, and cost-effectiveness. As a private, bootstrapped firm, it has maintained steady operations without external funding, focusing on niche custom synthesis where reliability and expertise are paramount. The peptide synthesis market is growing, driven by increasing R&D in therapeutic peptides and diagnostics. Biopeptide's long-standing presence and technical capabilities position it well to capture demand from both academic and commercial clients. However, the company faces competition from larger CROs and CDMOs. Its ability to scale capacity and invest in novel technologies will determine its future growth trajectory.

Upcoming Catalysts (preview)

• Q4 2026Expansion of GMP-grade manufacturing capacity60% success
• Q1 2027Strategic partnership with a mid-sized pharma for peptide drug development35% success
• Q3 2026Launch of an AI-assisted peptide design platform20% success